Clinical Report: Elevated FCRL5 Levels Correlate with Adverse Treatment Outcomes
Overview
This study investigates the prognostic value of FCRL5 in newly diagnosed multiple myeloma (NDMM), revealing that high FCRL5 expression is associated with poorer treatment responses and survival outcomes.
Background
Multiple myeloma (MM) is a prevalent hematologic malignancy characterized by significant clinical variability and treatment resistance. Current prognostic tools have limited predictive power, necessitating the identification of novel biomarkers to enhance risk stratification and treatment personalization. FCRL5, a B lineage-restricted protein, has emerged as a candidate due to its selective expression in myeloma and potential role in modulating immune responses.
Data Highlights
Outcome
High FCRL5 Expression
Low FCRL5 Expression
P-value
Complete Response
25.93%
51.85%
< 0.05
>= Very Good Partial Response
33.33%
70.37%
< 0.05
Minimal Residual Disease Negativity
29.63%
70.37%
< 0.05
Median Progression-Free Survival
10.6 months
Not reached
0.002
Median Overall Survival
13.2 months
Not reached
0.02
1-Year PFS Rate
21.43%
76.47%
0.004
Key Findings
High FCRL5 expression correlates with lower rates of complete response and minimal residual disease negativity.
Patients with high FCRL5 expression have significantly shorter median progression-free survival (10.6 months vs. not reached).
Overall survival is also adversely affected in patients with high FCRL5 levels (13.2 months vs. not reached).
High FCRL5 expression is an independent adverse prognostic factor for both progression-free survival and overall survival.
Baseline characteristics were balanced between high and low FCRL5 expression groups.
Clinical Implications
The findings indicate that FCRL5 expression is associated with treatment responses and survival outcomes in NDMM patients.
Conclusion
High FCRL5 expression is significantly associated with inferior treatment outcomes in NDMM.
